Aidan D. Atkins

Aidan D. Atkins

Auto-generated profile, based on publicly available information

Aidan D. Atkins

Texas A&M University Department of Biomedical Engineering, College Station, Texas, US

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
AAAidan D. Atkins
Aidan D. Atkins
MRMichael J. Reardon
Michael J. Reardon
MAMarvin D. Atkins
Marvin D. Atkins
Endovascular stent graft repair (EVAR) has revolutionized the management of aneurysms and dissections of the thoracic and abdominal aorta and is considered the first-line treatment in such pathologies. Initially designed for patients unfit for open repair, EVAR and thoracic endovascular aortic stent graft repair are associated with improved morbidity and mortality and a faster recovery process. The endovascular revolution of the aorta continues moving proximally, with fenestrated and branch stent grafts currently in clinical trials for the management of thoracoabdominal aortic aneurysms, and several branched thoracic devices are either approved or in trial for management of aortic arch pathologies. The final frontier in the endovascular management of the aorta is the aortic root and ascending aorta. The first early feasibility trial for management of type A aortic dissection has recently concluded with a multicenter phase 2 study slated for the spring of 2023. The following article updates the reader on the unique challenges of endovascular management of the ascending aorta and a look at the future technologies that will define this space.

7 March 2023 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
AAAidan D. Atkins
Aidan D. Atkins
MAMarvin D. Atkins
Marvin D. Atkins
Endovascular repair of abdominal and descending thoracic aortic aneurysms has become the standard of care due to improvements in morbidity and mortality compared to open surgical repair. Late durability, however, remains an issue because persistent endoleaks can lead to continued aneurysm expansion and eventual rupture, sometimes years following the original repair. Branched, fenestrated, and physician-modified endografts in the thoracic arch and thoracoabdominal aorta have extended the seal zone in order to mitigate the risks of proximal and distal endoleaks. This review summarizes the current state of branched, fenestrated, and physician-modified endografts used in complex aortic pathologies.

10 November 2026 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
JRJoshua D Robert
Joshua D Robert
SBStephan Bannikov
Stephan Bannikov
AAAidan D. Atkins
Aidan D. Atkins
MRMaham Rahimi
Maham Rahimi
Aortic disease and lower-extremity peripheral artery disease (PAD) generate substantial morbidity, mortality, and longitudinal imaging burden. Artificial intelligence (AI) is increasingly studied for vascular risk prediction, image analysis, procedural support, and surveillance, but the maturity of these applications is heterogeneous. This review evaluates recent AI applications in aortic disease and PAD, emphasizing the distinction between algorithmic performance, external validation, demonstrated workflow impact, and proven patient benefit. Automated image segmentation and opportunistic abdominal aortic aneurysm (AAA) detection have the most mature evidence base, including retrospective external validation and, for AI-assisted AAA case finding, nonrandomized evidence of improved downstream evaluation and follow-up. Conversely, while machine-learning models for vascular risk prediction and disease progression often report high retrospective accuracy, their clinical readiness remains strictly investigational. Across most aortic and PAD applications, there is a persistent lack of independent external validation, decision-curve analysis, and prospective testing against standard care. Image-fusion guidance has clinical evidence for reducing procedural resource use, but this evidence should not be conflated with autonomous AI or robotic navigation. Cardiovascular digital twins remain largely mechanistic, computational, or early-development frameworks. AI can augment vascular imaging and risk assessment, but high retrospective accuracy is not equivalent to clinical utility. Current guideline thresholds for repair, revascularization, and surveillance should not be altered on the basis of investigational radiomics or prediction models. Translation requires multicenter external validation, prospective workflow evaluation, calibration and net-benefit assessment, transparent reporting, and trials demonstrating improved patient outcomes.

17 July 2026 in Science Advances
Verified
Journal Article
Open access
SASamere Abolghasemzade
Samere Abolghasemzade
RBRyan Blanchard
Ryan Blanchard
CFChance French
Chance French
CDChristina R. Dollahon
Christina R. Dollahon
HPHarrison Pham
Harrison Pham
Tanmay LeleTanmay Lele
Tanmay Lele
Polyploid giant cancer cells (PGCCs) are chemoresistant tumor cells associated with poor patient outcomes. PGCCs in tissue are identified by their extremely large sizes and the presence of massive or several nuclei. Although nuclear dysmorphia is also a common characteristic of tumor cells, little is known about the shape of nuclei in PGCCs. We show that the nuclear lamina in giant nucleated PGCCs is highly wrinkled across diverse cancer patient tissues. We investigated the cause of this hyperwrinkling in ovarian PGCCs in vitro. Laminar hyperwrinkling in PGCCs was independent of cell shape or cytoskeletal forces. Instead, measurements combined with computational modeling show that laminar hyperwrinkling is an intrinsic property of PGCCs, arising from a disproportionate amount of laminar excess area. PGCCs also displayed attenuated mechanosensitivity of cell spreading and YAP nuclear localization compared with control cells. Thus, laminar hyperwrinkling may disrupt PGCC mechanobiological pathways, slowing their proliferation.